A Comparative Study of Degarelix Three-month Depot in Three Different Dosing Regimens in Patients With Prostate Cancer
Status:
Completed
Trial end date:
2006-11-01
Target enrollment:
Participant gender:
Summary
The rationale of the study was to evaluate different degarelix dosing regimens for a
three-month interval that was to produce and maintain castration in prostate cancer patients
through immediate and prolonged testosterone suppression, and to provide confirmatory
evidence of the safety of degarelix.